Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases

Bollen, Laurens; Wibmer, Christine; Wang, Miao; Linden, Y.M. van der; Leithner, Andreas; Bünger, Cody; Jensen, Anders Bonde; Fiocco, Marta; Bratschitsch, G.; Pondaag, Willem; Bovée, Judith V.M.G.; Dijkstra, P. D. Sander

doi:10.1007/s10585-014-9685-y

Cited by 19 publications

(32 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the remaining 33 records, nine were removed applying the exclusion criteria. The final set of bibliographic records reviewed was composed of 24 studies [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] ( Fig. 1 ).…”

Section: Resultsmentioning

confidence: 99%

Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data

Zhang

Zhu

Biskup

et al. 2018

Journal of Bone Oncology

View full text Add to dashboard Cite

PurposeThe aim was to systematically extrapolate the occurrence, risk factors, prognostic characteristics, management and outcome of bone metastases (BM) and skeletal related events (SREs) of breast cancer survivors in the real world clinical setting.MethodsA systematic literature search of PubMed, Web of Science, EMBASE OvidSP and EBSCO Academic Search Complete was conducted. Published prospective and retrospective papers investigating BM and SREs in breast cancer patients in non-trial settings were identified and systematically reviewed.ResultsTwenty-four studies met the inclusion criteria. Incidences of BM based on new diagnosis, length of BM-free interval (BMFI) and number and sites of BM were detected by 17 of 24 studies. Seven studies included in the review were subjected to analyses of risk factors for BM. Developments of SREs regarding the occurrence ratio of total and specific SREs, SERs-free interval (SREFI) and the first-line therapy for SREs were observed in 16 of 24 studies. Out of 5 studies, we extracted uni- and multivariate analysis of risk factor for SREs and out of 16 studies - predictors for survival in breast cancer patients with BM.ConclusionsBM and SREs are common problems in non-trial breast cancer populations. Patient demographics, clinical stage, tumor pathological type, molecular receptors status are significantly risk factors for incidence of BM, SREs and the survival. The unique characteristics of BM and SREs in breast cancer patients should be taken into account in future randomized controlled trials, as to optimize individual treatment options and assure a maximally long good quality of life.

show abstract

Section: Resultsmentioning

confidence: 99%

Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data

Zhang

Zhu

Biskup

et al. 2018

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…In bone lesions, triple-negative tumors were prevalent. Bollen et al 52 observed that patients with bone metastasis in the triple negative had mean survival of 6.7 months, unlike patients with positive receptors, whose survival was 22.5 months. In our survey, there was no correlation between the presence or absence of metastasis and the basal and non-basal like group.…”

Section: Discussionmentioning

confidence: 99%

“…Together with the classic parameters, like tumor size staging, axillary nodule and metastasis (TNM) and cell proliferation markers, other tumor markers have been used to predict tumor behavior, and the response to therapy in breast cancer. Among the markers verified by the immunohistochemical test, the most used in clinical practice are hormone receptors and HER-2 52 . The normal breast cell presents estrogen and progesterone receptors in their nuclei, detected through the immunohistochemical method.…”

Section: Discussionmentioning

confidence: 99%

Invasive triple negative breast cancer with basal and non-basal-like immunophenotypes: prognostic implications

Filho¹,

Ferreira²,

Lima³

et al. 2017

Mastology

View full text Add to dashboard Cite

Objectives: The objective of the study was to compare the postoperative staging and clinical development outcomes in a period of three years with the histopathological and immunohistochemical characteristics considered prognostic and/or predictive factors in patients being treated for triple negative type of breast cancer in the Barão Lucena Hospital, Recife, Pernambuco. Method: The study was conducted with 125 female patients suffering from triple negative breast cancer who underwent surgical treatment in the mastology service of Barão Lucena Hospital from 2009 to 2012. The clinical and pathological features of the tumors were studied and correlated with basal and non-basal subtypes. A descriptive data analysis was carried out using tables and/or graphs for qualitative variables. Association analysis was performed using χ 2 test for independence. In tables that showed expected frequency lower than 5, in more than 20% of cells, we used the Fisher's exact test. In addition, the odds ratio (OR) and the confidence interval (CI) for OR were calculated. In the entire analysis, a 5% significance level was considered. Results: Mean age was 49 years; regarding race, black was present in 83 (66.4%). The most common histological type was ductal, in 111 (88.8%). The pathological stage I/II was the most common, in 87 (69.6%) patients. A total of 71 patients (56.8%) showed no axillary metastasis. Regarding the type of surgery, the conservative one was performed in 57 (45.6%), including sectorectomy and oncoplastic surgery. The recurrence was present in 30 patients, basal in 16 (53.3%) patients and 14 (46.7%) in the non-basal, and bone metastasis was the most frequent. Conclusion: In this triple-negative tumor sample, the most important facts related to survival were: being aged less than 40 years, histological type, cytokeratin CK5/6 and higher significance level of the factors EGFR and KI-67.

show abstract

“…We found an age of more than 50 years, the presence of multiple SBM and triple negative phenotype to be associated with a worse prognosis after first diagnosis of bone metastases. In a recent study Bollen et al [ 18 ] reported a median survival time of 22.5 months (95 % CI 18.0–26.9) for the receptor positive category and 6.7 months (95 % CI 2.4–10.9) for the triple negative category ( p < 0.001). Therefore, patients with bone metastases from triple negative breast cancer have a significantly worse prognosis than those with a receptor positive phenotype.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer

et al. 2015

View full text Add to dashboard Cite

BackgroundBone metastases are an important clinical issue in women with breast cancer. Particularly, unstable spinal bone metastases (SBM) are a major cause of severe morbidity and reduced quality of life (QoL) due to frequent immobilization. Radiotherapy (RT) is the major treatment modality and is capable of promoting re-ossification and improving stability. Since local therapy response is excellent, survival of these patients with unstable SBM is of high clinical importance. We therefore conducted this analysis to assess survival and to determine prognostic factors for bone survival (BS) in women with breast cancer and unstable SBM.MethodsA total population of 92 women with unstable SBM from breast cancer who were treated with RT at our department between January 2000 and January 2012 was retrospectively investigated. We calculated overall survival (OS) and BS (time between first diagnosis of bone metastases until death) with the Kaplan-Meier method and assessed prognostic factors for BS with a Cox regression model.ResultsMean age at first diagnosis of breast cancer was 60.8 years ± SD 12.4 years. OS after 1, 2 and 5 years was 84.8, 66.3 and 50 %, respectively. BS after 1, 2 and 5 years was 62.0, 33.7 and 12 %, respectively. An age > 50 years (p < .001; HR 1.036 [CI 1.015–1.057]), the presence of a single bone metastasis (p = .002; HR 0.469 [CI 0.292–0.753]) and triple negative phenotype (p < .001; HR 1.068 [CI 0.933–1.125]) were identified as independent prognostic factors for BS.ConclusionsOur analysis demonstrated a short survival of women with breast cancer and unstable SBM. Age, presence of a solitary SBM and triple-negative phenotype correlated with survival. Our results may have an impact on therapeutic decisions in the future and offer a rationale for future prospective investigations.

show abstract

Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases

Cited by 19 publications

References 19 publications

Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data

Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data

Invasive triple negative breast cancer with basal and non-basal-like immunophenotypes: prognostic implications

Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer

Contact Info

Product

Resources

About